Hancock Jaffe Laboratories Inc (NASDAQ:HJLI) Short Interest Update

Hancock Jaffe Laboratories Inc (NASDAQ:HJLI) was the target of a large decline in short interest during the month of June. As of June 30th, there was short interest totalling 20,900 shares, a decline of 88.0% from the May 30th total of 173,600 shares. Approximately 0.4% of the shares of the company are sold short. Based on an average daily trading volume, of 219,600 shares, the short-interest ratio is presently 0.1 days.

Separately, Zacks Investment Research lowered shares of Hancock Jaffe Laboratories from a “buy” rating to a “hold” rating in a research note on Wednesday, June 26th.

HJLI remained flat at $$1.00 during mid-day trading on Friday. 90,935 shares of the company’s stock were exchanged, compared to its average volume of 212,159. The company has a debt-to-equity ratio of 0.27, a quick ratio of 1.60 and a current ratio of 1.60. The company’s 50-day moving average price is $1.31. Hancock Jaffe Laboratories has a 1-year low of $0.87 and a 1-year high of $3.57.



An institutional investor recently bought a new position in Hancock Jaffe Laboratories stock. Jane Street Group LLC acquired a new stake in shares of Hancock Jaffe Laboratories Inc (NASDAQ:HJLI) in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund acquired 31,692 shares of the company’s stock, valued at approximately $47,000. Jane Street Group LLC owned 0.27% of Hancock Jaffe Laboratories at the end of the most recent reporting period. 1.10% of the stock is currently owned by institutional investors.

Hancock Jaffe Laboratories Company Profile

Hancock Jaffe Laboratories, Inc, a development stage medical device company, develops and sells biological tissue solutions to treat patients with coronary, vascular, end stage renal, and peripheral arterial diseases in the United States and Europe. The company develops and manufactures implantable cardiovascular bioprosthetic devices for patients with cardiovascular disease, peripheral arterial and venous disease, and end stage renal disease.

Further Reading: Backdoor Roth IRA Conversion and Strategy

Receive News & Ratings for Hancock Jaffe Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hancock Jaffe Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.